- Home
- MKTX vs LEGN Comparison
MKTX vs LEGN Comparison
Compare MKTX & LEGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MKTX
- LEGN
- Stock Information
- Founded
- MKTX 2000
- LEGN 2014
- Country
- MKTX United States
- LEGN United States
- Employees
- MKTX N/A
- LEGN N/A
- Industry
- MKTX Investment Bankers/Brokers/Service
- LEGN Biotechnology: Pharmaceutical Preparations
- Sector
- MKTX Finance
- LEGN Health Care
- Exchange
- MKTX Nasdaq
- LEGN Nasdaq
- Market Cap
- MKTX 8.0B
- LEGN 7.0B
- IPO Year
- MKTX 2004
- LEGN 2020
- Fundamental
- Price
- MKTX $217.85
- LEGN $28.91
- Analyst Decision
- MKTX Buy
- LEGN Strong Buy
- Analyst Count
- MKTX 9
- LEGN 13
- Target Price
- MKTX $241.78
- LEGN $75.67
- AVG Volume (30 Days)
- MKTX 531.3K
- LEGN 1.7M
- Earning Date
- MKTX 05-07-2025
- LEGN 05-13-2025
- Dividend Yield
- MKTX 1.39%
- LEGN N/A
- EPS Growth
- MKTX N/A
- LEGN N/A
- EPS
- MKTX 5.76
- LEGN N/A
- Revenue
- MKTX $815,355,000.00
- LEGN $728,303,000.00
- Revenue This Year
- MKTX $8.33
- LEGN $64.21
- Revenue Next Year
- MKTX $9.84
- LEGN $53.69
- P/E Ratio
- MKTX $37.83
- LEGN N/A
- Revenue Growth
- MKTX 7.33
- LEGN 112.46
- 52 Week Low
- MKTX $186.84
- LEGN $27.34
- 52 Week High
- MKTX $296.68
- LEGN $60.87
- Technical
- Relative Strength Index (RSI)
- MKTX 48.40
- LEGN 39.95
- Support Level
- MKTX $209.80
- LEGN $28.14
- Resistance Level
- MKTX $223.09
- LEGN $31.12
- Average True Range (ATR)
- MKTX 6.43
- LEGN 1.87
- MACD
- MKTX -0.69
- LEGN -0.16
- Stochastic Oscillator
- MKTX 34.94
- LEGN 25.95
About MKTX MarketAxess Holdings Inc.
Founded in 2000, MarketAxess is a leading electronic fixed-income trading platform that connects broker/dealers and institutional investors. The company is primarily focused on credit based fixed income securities with its main trading products being US investment-grade and high-yield bonds, Eurobonds, and Emerging Market corporate debt. Recently the company has expanded more aggressively into Treasuries and municipal bonds with the acquisitions of LiquidityEdge and MuniBrokers in 2019 and 2021, respectively. The company also provides pre- and post-trade services with its acquisition of Regulatory Reporting Hub from Deutsche Börse Group in 2020 adding to its product offerings.
About LEGN Legend Biotech Corporation
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's lead product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.